Affymax $50M+ Offering May Help Revive Peginesatide NDA
By Tom Wall
Monday, March 21, 2011
Affymax Inc. is reviving efforts to get FDA approval of peginesatide previously known as Hematide for treatment of anemia in chronic renal failure patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.